AmitisGen TECH Dev Group Personalized and Precision Medicine Journal 3115-7874 6 22 2021 09 20 A Case Report: The Potential Clinical Benefits of Comprehensive Molecular Profiling in an Aggressive NSCL Grade IV 23 26 246866 10.22034/pmj.2021.246866 EN Elaheh Aliakbari RayaaGen Accelerator Director, Tehran, Iran. Mahnaz Saremi Reference health laboratory, Ministry of health and medical education Journal Article 2021 07 01 We present a Non-Small Cell Lung Cancer Grade IV patient, diagnosed at 46 years of age, with multiple relapse from the diagnosis and demonstrating a poor prognosis after 3 cycles of treatments. A clinical comprehensive genomic profile was performed with the goal of finding potential actionable molecular alterations. The patient showed significant symptomatic and laboratory improvement with a combination chemotherapy determined by the molecular profiling, which would otherwise not have been considered. The mentioned approach was conducted since no other targeted therapies seemed actionable for him. EML4-ALK fusion TNM stage Erlotinib Osimertinib Next-generation sequencing Immunohistochemistry https://www.pmjournal.ir/article_246866_ac91109b7d19525d900b5db07661c3b9.pdf